1. Home
  2. VYGR vs EMF Comparison

VYGR vs EMF Comparison

Compare VYGR & EMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • EMF
  • Stock Information
  • Founded
  • VYGR 2013
  • EMF 1987
  • Country
  • VYGR United States
  • EMF United States
  • Employees
  • VYGR N/A
  • EMF N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • EMF Finance/Investors Services
  • Sector
  • VYGR Health Care
  • EMF Finance
  • Exchange
  • VYGR Nasdaq
  • EMF Nasdaq
  • Market Cap
  • VYGR 191.9M
  • EMF 180.1M
  • IPO Year
  • VYGR 2015
  • EMF N/A
  • Fundamental
  • Price
  • VYGR $3.17
  • EMF $13.05
  • Analyst Decision
  • VYGR Strong Buy
  • EMF
  • Analyst Count
  • VYGR 9
  • EMF 0
  • Target Price
  • VYGR $14.86
  • EMF N/A
  • AVG Volume (30 Days)
  • VYGR 282.0K
  • EMF 29.3K
  • Earning Date
  • VYGR 05-06-2025
  • EMF 01-01-0001
  • Dividend Yield
  • VYGR N/A
  • EMF 6.16%
  • EPS Growth
  • VYGR N/A
  • EMF N/A
  • EPS
  • VYGR N/A
  • EMF N/A
  • Revenue
  • VYGR $66,958,000.00
  • EMF N/A
  • Revenue This Year
  • VYGR N/A
  • EMF N/A
  • Revenue Next Year
  • VYGR $2.04
  • EMF N/A
  • P/E Ratio
  • VYGR N/A
  • EMF N/A
  • Revenue Growth
  • VYGR N/A
  • EMF N/A
  • 52 Week Low
  • VYGR $2.75
  • EMF $10.58
  • 52 Week High
  • VYGR $9.55
  • EMF $12.67
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 40.49
  • EMF 60.38
  • Support Level
  • VYGR $3.46
  • EMF $12.91
  • Resistance Level
  • VYGR $3.69
  • EMF $13.25
  • Average True Range (ATR)
  • VYGR 0.18
  • EMF 0.10
  • MACD
  • VYGR 0.00
  • EMF 0.07
  • Stochastic Oscillator
  • VYGR 0.00
  • EMF 80.69

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.

Share on Social Networks: